Literature DB >> 11819475

Increased prevalence of intestinal inflammation in patients with liver cirrhosis.

Osamu Saitoh, Kazunori Sugi, Keishi Lojima, Hisashi Matsumoto, Ken Nakagawa, Masanobu Kayazawa, Seigou Tanaka, Tsutomu Teranishi, Ichiro Hirata.   

Abstract

AIM:To investigate the pathophysiology of the digestive tract in patients with liver cirrhosis.
METHODS: In 42 cirrhotic patients and 20 control subjects, the following fecal proteins were measured by enzyme-linked immunosorbent assay: albumin (Alb), transferrin (Tf), and alpha(1)antitrypsin (alpha(1)-AT) as a marker for intestinal protein loss, hemoglobin (Hb) for bleeding, PMN-elastase for intestinal inflammation, and secretory IgA for intestinal immunity.
RESULTS: The fecal concentrations of Hb, Alb, Tf,alpha(1)-AT, and PMN-elastase were increased in 13 (31%), 8(19%), 10(24%), 6(14%), and 11 (26%) cases among 42 patients, respectively. Fecal concentration of secretory IgA was decreased in 7 (17%) of 42 patients. However, these fecal concentrations were not related to the severity or etiology of liver cirrhosis. The serum Alb level was significantly decreased in patients with intestinal protein loss compared to that in patients without intestinal protein loss.
CONCLUSION: These findings suggest that: (1)besides the well-known pathological conditions, such as bleeding and protein loss, intestinal inflammation and decreased intestinal immunity are found in cirrhotic patients; (2)intestinal protein loss contributes to hypoalbuminemia in cirrhotic patients, and (3) intestinal inflammation should not be over looked in cirrhotic patients, since it may contribute to or cause intestinal protein loss and other various pathological conditions.

Entities:  

Year:  1999        PMID: 11819475      PMCID: PMC4688607          DOI: 10.3748/wjg.v5.i5.391

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  23 in total

1.  Portal hypertensive gastropathy in patients with cirrhosis.

Authors:  T Iwao; A Toyonaga; M Sumino; K Takagi; K Oho; M Nishizono; K Ohkubo; R Inoue; E Sasaki; K Tanikawa
Journal:  Gastroenterology       Date:  1992-06       Impact factor: 22.682

2.  Colonic disease in cirrhotic patients with portal hypertension: an endoscopic and clinical evaluation.

Authors:  G Bresci; L Gambardella; G Parisi; G Federici; M Bertini; G Rindi; S Metrangolo; E Tumino; M Bertoni; M C Cagno; A Capria
Journal:  J Clin Gastroenterol       Date:  1998-04       Impact factor: 3.062

3.  Bile acid metabolism in patients with cirrhosis. II. Cholic and chenodeoxycholic acid metabolism.

Authors:  Z R Vlahcevic; P Juttijudata; C C Bell; L Swell
Journal:  Gastroenterology       Date:  1972-06       Impact factor: 22.682

Review 4.  Gastrointestinal dysfunction in liver disease and portal hypertension. Gut-liver interactions revisited.

Authors:  E M Quigley
Journal:  Dig Dis Sci       Date:  1996-03       Impact factor: 3.199

5.  Protein loss into the gastrointestinal tract in cirrhosis of the liver.

Authors:  F L Iber
Journal:  Am J Clin Nutr       Date:  1966-10       Impact factor: 7.045

6.  The forms and the levels of fecal PMN-elastase in patients with colorectal diseases.

Authors:  O Saitoh; K Sugi; R Matsuse; K Uchida; H Matsumoto; K Nakagawa; K Takada; M Yoshizumi; I Hirata; K Katsu
Journal:  Am J Gastroenterol       Date:  1995-03       Impact factor: 10.864

7.  Gastric lesions in portal hypertension: inflammatory gastritis or congestive gastropathy?

Authors:  T T McCormack; J Sims; I Eyre-Brook; H Kennedy; J Goepel; A G Johnson; D R Triger
Journal:  Gut       Date:  1985-11       Impact factor: 23.059

8.  Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins.

Authors:  K Sugi; O Saitoh; I Hirata; K Katsu
Journal:  Am J Gastroenterol       Date:  1996-05       Impact factor: 10.864

9.  Colonic findings in cirrhotics with portal hypertension. A prospective colonoscopic and histological study.

Authors:  N Scandalis; A Archimandritis; K Kastanas; C Spiliadis; B Delis; Z Manika
Journal:  J Clin Gastroenterol       Date:  1994-06       Impact factor: 3.062

10.  Portal hypertensive colopathy. A new entity.

Authors:  S Naveau; P Bedossa; T Poynard; B Mory; J C Chaput
Journal:  Dig Dis Sci       Date:  1991-12       Impact factor: 3.199

View more
  18 in total

1.  Plasma endothelin in patients with endotoxemia and dynamic comparison between vasoconstrictor and vasodilator in cirrhotic patients.

Authors:  F Liu; J X Li; C M Li; X S Leng
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

2.  Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications.

Authors:  Georgios I Tsiaoussis; Stelios F Assimakopoulos; Athanassios C Tsamandas; Christos K Triantos; Konstantinos C Thomopoulos
Journal:  World J Hepatol       Date:  2015-08-18

3.  Phagocytic and oxidative burst activity of neutrophils in the end stage of liver cirrhosis.

Authors:  Anatol Panasiuk; Jolanta Wysocka; Elzbieta Maciorkowska; Bozena Panasiuk; Danuta Prokopowicz; Janusz Zak; Karol Radomski
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

4.  Expression of lipopolysaccharide binding protein and its receptor CD14 in experimental alcoholic liver disease.

Authors:  G Q Zuo; J P Gong; C A Liu; S W Li; X C Wu; K Yang; Y Li
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

5.  Presence of anti-microbial antibodies in liver cirrhosis--a tell-tale sign of compromised immunity?

Authors:  Maria Papp; Gary L Norman; Zsuzsanna Vitalis; Istvan Tornai; Istvan Altorjay; Ildiko Foldi; Miklos Udvardy; Zakera Shums; Tamas Dinya; Peter Orosz; Bela Lombay; Gabriella Par; Alajos Par; Gabor Veres; Timea Csak; Janos Osztovits; Ferenc Szalay; Peter Laszlo Lakatos
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

6.  Acute rectocolitis following endoscopy in health check-up patients--glutaraldehyde colitis or ischemic colitis?

Authors:  Chao-Wen Hsu; Chieh-Hsin Lin; Jui-Ho Wang; Hsin-Tai Wang; Wen-Chieh Ou; Tai-Ming King
Journal:  Int J Colorectal Dis       Date:  2009-07-28       Impact factor: 2.571

Review 7.  Novel prevention strategies for bacterial infections in cirrhosis.

Authors:  Kathleen Yan; Guadalupe Garcia-Tsao
Journal:  Expert Opin Pharmacother       Date:  2016-02-23       Impact factor: 3.889

Review 8.  Gut epithelial barrier dysfunction in human immunodeficiency virus-hepatitis C virus coinfected patients: Influence on innate and acquired immunity.

Authors:  Mercedes Márquez; Clotilde Fernández Gutiérrez del Álamo; José Antonio Girón-González
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

Review 9.  Microbiota, cirrhosis, and the emerging oral-gut-liver axis.

Authors:  Chathur Acharya; Sinem Esra Sahingur; Jasmohan S Bajaj
Journal:  JCI Insight       Date:  2017-10-05

Review 10.  Inflammatory status in human hepatic cirrhosis.

Authors:  María Martínez-Esparza; María Tristán-Manzano; Antonio J Ruiz-Alcaraz; Pilar García-Peñarrubia
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.